Noncentral Nervous System Systemic Embolism in Patients With Atrial Fibrillation: Results From ROCKET AF (Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).
作者信息
Orgel Ryan, Wojdyla Daniel, Huberman David, Halperin Jonathan L, Breithardt Günter, Singer Daniel E, Fox Keith A A, Hankey Graeme J, Mahaffey Kenneth W, Jones W Schuyler, Patel Manesh R
机构信息
From the Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC (R.O., D.W., W.S.J., M.R.P.); Department of Statistics, North Carolina State University, Raleigh (D.H.); Mount Sinai Medical Center, New York, NY (J.L.H.); Department of Cardiovascular Medicine, Hospital of the University of Münster, Germany (G.B.); Massachusetts General Hospital and Harvard Medical School, Boston (D.E.S.); University of Edinburgh and Royal Infirmary of Edinburgh, Scotland, United Kingdom (K.A.A.F.); School of Medicine and Pharmacology, University of Western Australia, Crawley (G.J.H.); and Stanford University School of Medicine, CA (K.W.M.).
出版信息
Circ Cardiovasc Qual Outcomes. 2017 May;10(5). doi: 10.1161/CIRCOUTCOMES.116.003520.
Abstract
摘要
相似文献
1
Noncentral Nervous System Systemic Embolism in Patients With Atrial Fibrillation: Results From ROCKET AF (Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).心房颤动患者的非中枢神经系统系统性栓塞：ROCKET AF研究结果（利伐沙班每日一次口服直接抑制Xa因子与维生素K拮抗剂预防心房颤动患者中风和栓塞的试验）
Circ Cardiovasc Qual Outcomes. 2017 May;10(5). doi: 10.1161/CIRCOUTCOMES.116.003520.
2
Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: the Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial).利伐沙班用于糖尿病合并非瓣膜性心房颤动患者的疗效和安全性：利伐沙班每日一次口服直接抑制Xa因子与维生素K拮抗剂预防心房颤动中风和栓塞试验（ROCKET AF试验）
Am Heart J. 2015 Oct;170(4):675-682.e8. doi: 10.1016/j.ahj.2015.07.006. Epub 2015 Jul 17.
3
Outcome of Patients Receiving Thrombolytic Therapy While on Rivaroxaban for Nonvalvular Atrial Fibrillation (from Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).接受利伐沙班治疗非瓣膜性心房颤动时接受溶栓治疗的患者的结局（来自利伐沙班每日一次口服直接Xa因子抑制与维生素K拮抗剂预防心房颤动中风和栓塞试验）
Am J Cardiol. 2017 Nov 15;120(10):1837-1840. doi: 10.1016/j.amjcard.2017.07.095. Epub 2017 Aug 7.
4
Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF).在每日口服一次利伐沙班、直接 Xa 因子抑制剂与维生素 K 拮抗剂预防心房颤动卒中及栓塞试验（ROCKET AF）中，与华法林相比，利伐沙班在老年非瓣膜性心房颤动患者中的疗效和安全性。
Circulation. 2014 Jul 8;130(2):138-46. doi: 10.1161/CIRCULATIONAHA.113.005008. Epub 2014 Jun 3.
5
Relation of Risk of Stroke in Patients With Atrial Fibrillation to Body Mass Index (from Patients Treated With Rivaroxaban and Warfarin in the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation Trial).心房颤动患者中风风险与体重指数的关系（来自利伐沙班与华法林治疗的患者，利伐沙班每日一次口服直接Xa因子抑制与维生素K拮抗剂预防心房颤动试验中的中风和栓塞试验）
Am J Cardiol. 2017 Jun 15;119(12):1989-1996. doi: 10.1016/j.amjcard.2017.03.028. Epub 2017 Mar 29.
6
[Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: A retrospective analysis of the rivaroxaban once daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF)].地高辛在心房颤动患者中的应用及不良心血管结局：利伐沙班每日一次口服直接抑制因子Xa与维生素K拮抗剂预防心房颤动患者卒中及栓塞的随机对照试验（ROCKET AF）的回顾性分析
Semergen. 2016 May-Jun;42(4):260-2. doi: 10.1016/j.semerg.2015.08.008. Epub 2015 Dec 1.
7
Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts.肾功能障碍作为非瓣膜性心房颤动患者中风和全身性栓塞的预测因子：ROCKET AF（利伐沙班每日一次，口服，直接 Xa 因子抑制与维生素 K 拮抗剂预防中风和房颤试验）和 ATRIA（心房颤动抗凝和危险因素）研究队列中 R(2)CHADS(2)指数的验证。
Circulation. 2013 Jan 15;127(2):224-32. doi: 10.1161/CIRCULATIONAHA.112.107128. Epub 2012 Dec 3.
8
Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study.利伐沙班每日一次、口服、直接 Xa 因子抑制与维生素 K 拮抗剂用于预防卒中和心房颤动的栓塞试验：ROCKET AF 研究的原理和设计。
Am Heart J. 2010 Mar;159(3):340-347.e1. doi: 10.1016/j.ahj.2009.11.025.
9
Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation).与大出血事件相关的因素：来自 ROCKET AF 试验的观察结果（每日一次口服直接因子 Xa 抑制剂利伐沙班与维生素 K 拮抗剂预防心房颤动卒中和栓塞的比较试验）。
J Am Coll Cardiol. 2014 Mar 11;63(9):891-900. doi: 10.1016/j.jacc.2013.11.013. Epub 2013 Dec 4.
10
Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: results from the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF).非瓣膜性心房颤动患者中利伐沙班与华法林临时中断治疗的结局：每日口服一次、直接 Xa 因子抑制剂利伐沙班与维生素 K 拮抗剂预防心房颤动血栓栓塞（ROCKET AF）研究。
Circulation. 2014 May 6;129(18):1850-9. doi: 10.1161/CIRCULATIONAHA.113.005754. Epub 2014 Feb 19.
引用本文的文献
1
RETRACTED: Safety of radiofrequency ablation for reducing inflammatory cytokine levels and the left atrial diameter in patients with atrial fibrillation.撤回：射频消融术降低心房颤动患者炎症细胞因子水平及左心房直径的安全性。
J Int Med Res. 2020 Sep;48(9):300060520949760. doi: 10.1177/0300060520949760.
2
Clinical characteristics and thrombotic risk of atrial fibrillation with obstructive sleep apnea: results from a multi-center atrial fibrillation registry study.伴有阻塞性睡眠呼吸暂停的心房颤动的临床特征和血栓栓塞风险：一项多中心心房颤动登记研究结果。
BMC Cardiovasc Disord. 2022 Jul 25;22(1):331. doi: 10.1186/s12872-022-02773-9.
3
Relationship Between Visceral Infarction and Ischemic Stroke Subtype.内脏梗死与缺血性卒中亚型之间的关系。
Stroke. 2018 Mar;49(3):727-729. doi: 10.1161/STROKEAHA.117.020035. Epub 2018 Jan 25.
本文引用的文献
1
Systemic, noncerebral, arterial embolism in 21,105 patients with atrial fibrillation randomized to edoxaban or warfarin: results from the Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction Study 48 trial.21105例心房颤动患者随机接受依度沙班或华法林治疗后的全身性、非脑性动脉栓塞：心房颤动-心肌梗死溶栓研究48试验中下一代Xa因子有效抗凝治疗的结果
Am Heart J. 2015 Oct;170(4):669-74. doi: 10.1016/j.ahj.2015.06.020. Epub 2015 Jul 2.
2
Systemic Embolic Events (SEE) in Atrial Fibrillation: SEEing Embolic Risk More Clearly.心房颤动中的全身性栓塞事件：更清晰地认识栓塞风险
Circulation. 2015 Sep 1;132(9):787-9. doi: 10.1161/CIRCULATIONAHA.115.018172. Epub 2015 Jul 29.
3
Extracranial Systemic Embolic Events in Patients With Nonvalvular Atrial Fibrillation: Incidence, Risk Factors, and Outcomes.非瓣膜性心房颤动患者的颅外系统栓塞事件：发生率、危险因素和结局。
Circulation. 2015 Sep 1;132(9):796-803. doi: 10.1161/CIRCULATIONAHA.114.013243. Epub 2015 Jul 29.
4
Trends in the incidence, treatment, and outcomes of acute lower extremity ischemia in the United States Medicare population.美国医疗保险人群急性下肢缺血的发病率、治疗及转归趋势
J Vasc Surg. 2014 Sep;60(3):669-77.e2. doi: 10.1016/j.jvs.2014.03.244. Epub 2014 Apr 24.
5
Thromboembolism associated with atrial fibrillation as a cause of limb and organ ischemia.与心房颤动相关的血栓栓塞是导致肢体和器官缺血的原因。
Adv Clin Exp Med. 2013 Nov-Dec;22(6):865-73.
6
Twenty-year analysis of trends in the incidence and in-hospital mortality for lower-extremity arterial thromboembolism.下肢动脉血栓栓塞症发病率和住院死亡率的 20 年分析。
Circulation. 2013 Jul 9;128(2):115-21. doi: 10.1161/CIRCULATIONAHA.113.003543. Epub 2013 Jun 5.
7
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.利伐沙班与华法林用于非瓣膜性心房颤动。
N Engl J Med. 2011 Sep 8;365(10):883-91. doi: 10.1056/NEJMoa1009638. Epub 2011 Aug 10.
8
Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study.利伐沙班每日一次、口服、直接 Xa 因子抑制与维生素 K 拮抗剂用于预防卒中和心房颤动的栓塞试验：ROCKET AF 研究的原理和设计。
Am Heart J. 2010 Mar;159(3):340-347.e1. doi: 10.1016/j.ahj.2009.11.025.
9
Incident thromboembolism in the aorta and the renal, mesenteric, pelvic, and extremity arteries after discharge from the hospital with a diagnosis of atrial fibrillation.出院诊断为心房颤动后，主动脉及肾动脉、肠系膜动脉、盆腔动脉和四肢动脉发生的血栓栓塞事件。
Arch Intern Med. 2001 Jan 22;161(2):272-6. doi: 10.1001/archinte.161.2.272.
10
Thromboembolic complications in atrial fibrillation.
Stroke. 1990 Jan;21(1):4-13. doi: 10.1161/01.str.21.1.4.
Zotero 插件